Featured Research

from universities, journals, and other organizations

Genetic variation increases risk of metabolic side effects in children on some antipsychotics

Date:
January 24, 2012
Source:
Child & Family Research Institute
Summary:
Researchers have found a genetic variation predisposing children to six-times greater risk of developing metabolic syndrome when taking second-generation anti-psychotic medications. Metabolic syndrome is a cluster of conditions that are risk factors for cardiovascular disease. The study showed a close association with two conditions in particular: high blood pressure and elevated fasting blood sugar levels, which is a precursor to diabetes.

Researchers have found a genetic variation predisposing children to six-times greater risk of developing metabolic syndrome when taking second-generation anti-psychotic medications. Metabolic syndrome is a cluster of conditions that are risk factors for cardiovascular disease. The study showed a close association with two conditions in particular: high blood pressure and elevated fasting blood sugar levels, which is a precursor to diabetes. The research is published recently in the medical research journal Translational Psychiatry.

"This is the first report of an underlying biological factor predisposing children to complications associated with second-generation anti-psychotic medication use," says Dr. Dina Panagiotopoulos, study co-author, clinician scientist at the Child & Family Research Institute (CFRI), pediatric endocrinologist at BC Children's Hospital, and assistant professor, Department of Pediatrics, University of British Columbia (UBC).

"It's concerning because these children take medications to treat a chronic disease -- mental illness -- and then develop risk factors for a second chronic disease," says Dr. Angela Devlin, study co-author, CFRI scientist and assistant professor in the UBC Department of Pediatrics.

Second-generation anti-psychotics are prescribed to approximately 5500 children and youth in British Columbia for psychotic disorders, mood and anxiety disorders, attention deficit hyperactivity disorder, autism spectrum disorders, adjustment disorders and substance abuse. Of these medications, the two most commonly prescribed in B.C. are quetiapine (Seroquel®) and risperidone (Risperdal®).

For the study, researchers assessed 209 children who were inpatients between April 2008 and June 2011 at the Child & Adolescent Psychiatry Department at BC Children's Hospital, an agency of the Provincial Health Services Authority. Their average age was 13 years, and 105 of the children were treated with second-generation anti-psychotics while 112 did not use these drugs. DNA analysis showed that eight per cent of children from both groups had a genetic variation called C677T on the MTHFR gene. Children with the MTHFR C677T variant who used these medications were six-times more likely to have metabolic syndrome.

The researchers targeted the MTHFR C677T variant because it is known to be associated with metabolic syndrome in adults who have schizophrenia, and with cardiovascular disease in adults who don't have psychiatric illness.

Dr. Devlin and Dr. Panagiotopoulos say their discovery is an important step to preventing and managing metabolic complications associated with second-generation antipsychotic medications. It is critical to reduce these risks in childhood because adults with mental illness have a 19 per cent increased mortality rate that is largely due to cardiovascular disease risk.

The MTHFR gene is involved in metabolizing the B-vitamin folate.

"We now plan to assess B vitamin status and dietary intake in children who take these medications to gain a better understanding of this association," says Dr. Panagiotopoulos.

This study was funded by CFRI and the Canadian Diabetes Association.

Dr. Panagiotopoulos's previous research on the metabolic side effects of anti-psychotics in children led to national recommendations for clinicians on monitoring and managing the care of children who take these medications. The recommendations were published in the Journal of the Canadian Academy of Child and Adolescent Psychiatry in August 2011 and in Pediatrics and Child Health in November 2011.


Story Source:

The above story is based on materials provided by Child & Family Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. A M Devlin, Y F Ngai, R Ronsley, C Panagiotopoulos. Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics. Translational Psychiatry, 2012; 2 (1): e71 DOI: 10.1038/tp.2011.68

Cite This Page:

Child & Family Research Institute. "Genetic variation increases risk of metabolic side effects in children on some antipsychotics." ScienceDaily. ScienceDaily, 24 January 2012. <www.sciencedaily.com/releases/2012/01/120124140311.htm>.
Child & Family Research Institute. (2012, January 24). Genetic variation increases risk of metabolic side effects in children on some antipsychotics. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2012/01/120124140311.htm
Child & Family Research Institute. "Genetic variation increases risk of metabolic side effects in children on some antipsychotics." ScienceDaily. www.sciencedaily.com/releases/2012/01/120124140311.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) — The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) — Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) — A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) — The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins